Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Human Immunodeficiency Virus

Human Papillomavirus- 6, 11, 16, 18

Eligibility:

All Genders

12-26 years

Phase:

PHASE1

Brief Summary

Background: * Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection. Most people do not h...

Detailed Description

Background: Human papilloma virus (HPV) is one of the most common sexually transmitted diseases and a significant cause of cutaneous genital warts and anogenital cancer. Infection with high-risk, on...

Eligibility Criteria

Inclusion

  • ELIGIBILITY CRITERIA:
  • Cohort 1 Inclusion and Exclusion Eligibility Criteria:
  • INCLUSION CRITERIA:
  • 1.1.1 Age 12 to 26 years
  • 1.1.2 Females and males
  • 1.1.3 Human immunodeficiency virus (HIV)-positive
  • 1.1.4 Cluster of differentiation 4 (CD4) cell count and Human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) level parameters
  • CD4 cell count greater than or equal to 350 cells/mm(3)
  • HIV-1 RNA level by reverse transcription-polymerase chain reaction (RT PCR) less than or equal to 20,000 copies/ml
  • 1.1.5 On stable highly active antiretroviral therapy (HAART) regimen for greater than or equal to 6 months with CD4 and viral load parameters as outlined in 2.1.1.4
  • 1.1.6 Patients greater than or equal to 18 years willing to provide informed consent or parent/guardian willing to provide informed consent for minor children less than 18 years of age.
  • 1.1.7 Informed assent for patients 12-17 years of age (Optional at the discretion of the Principal Investigator and Parent/Guardian based on maturity level of minor)
  • 1.1.8 Willing to use acceptable forms of contraception, if applicable, or abstinence to prevent pregnancy.
  • EXCLUSION CRITERIA:
  • 1.1.9 Any of the following hematologic abnormalities
  • Hemoglobin less than 10.0 g/dL
  • Neutrophil count less than 1500/mm(3)
  • Platelet count less than 75,000/mm(3)
  • Prothrombin time (PT) or partial thromboplastin time (PTT) greater than or equal to 1.5 times upper limits of normal (ULN) (with the exception of patients with known clotting disorders or known lupus anticoagulant).
  • 1.1.10 Any of the following hepatic abnormalities
  • Alanine transaminase (ALT)/ serum glutamate-pyruvate transaminase (SGPT) and/or Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) greater than 2.5 times ULN
  • Total bilirubin greater than 1.5 times ULN unless attributable to protease inhibitor therapy.
  • 1.1.11 Positive tests (antibody and/or antigen) for hepatitis B and hepatitis C viruses, unless the result is consistent with prior vaccination or prior infection with full recovery.
  • 1.1.12 Acute infection requiring therapy at time of enrollment. Participants may be eligible for study after being on stable and appropriate anti-infective therapy.
  • 1.1.13 Chemotherapy for active cancer.
  • 1.1.14 Documented history of non-adherence to antiretroviral treatment regimen within 12 months of study entry.
  • 1.1.15 Pregnancy or breastfeeding.
  • 1.1.16 Use of immunosuppressive or immunomodulating agents within 8 weeks of study enrollment. Note: patients receiving oral corticosteroids for management of asthma or contact hypersensitivity for less than or equal to 14 days in duration will be allowed to enroll as long as it has been greater than or equal to 30 days since oral corticosteroid administration.
  • 1.1.17 Known immediate hypersensitivity to yeast or any of the vaccine components.
  • 1.1.18 Use of investigational agents within 4 weeks prior to study enrollment.
  • 1.1.19 Active external genital warts requiring treatment or cervical intraepithelial neoplasia (CIN)2/3
  • 1.1.20 Any clinically significant diseases (other than HIV infection) or findings during study screening that, in the opinion of the Principal Investigator or Lead Associate Investigator, may interfere with the study.
  • Cohort 2 Inclusion and Exclusion Eligibility Criteria:
  • Inclusion Criteria
  • 1.2.1 Age 12 to 26 years
  • 1.2.2 Females and males
  • 1.2.3 HIV-positive
  • 1.2.4 CD4 cell count and HIV-1 RNA level parameters
  • CD4 cell count greater than or equal to 500 cells/mm(3)
  • HIV-1 RNA level by RT PCR less than or equal to 20,000 copies/ml.
  • 1.2.5 Not receiving antiretroviral treatment with CD4 and viral load parameters as outlined in 2.1.2.4.
  • 1.2.6 Patients greater than or equal to 18 years willing to provide informed consent or parent/guardian willing to provide informed consent for minor children less than 18 years of age.
  • 1.2.7 Informed assent for patients 12-17 years of age (Optional at the discretion of the Principal Investigator and Parent/Guardian based on maturity level of minor)
  • 1.2.8 Willing to use acceptable forms of contraception, if applicable, or abstinence to prevent pregnancy.
  • EXCLUSION CRITERIA:
  • 1.2.9 Any of the following hematologic abnormalities:
  • Hemoglobin less than 10.0 g/dL
  • Neutrophil count less than 1500/mm(3)
  • Platelet count less than 75,000/mm(3)
  • PT or PTT greater than or equal to 1.5 times ULN (with the exception of patients with known clotting disorders or known lupus anticoagulant).
  • 1.2.10 Any of the following hepatic abnormalities
  • ALT/SGPT and/or AST/SGOT greater than 2.5 times ULN
  • Total bilirubin greater than 1.5 times ULN unless attributable to protease inhibitor therapy.
  • 1.2.11 Positive tests (antibody and/or antigen) for hepatitis B and hepatitis C viruses, unless the result is consistent with prior vaccination or prior infection with full recovery.
  • 1.2.12 Acute infection requiring therapy at time of enrollment. Participants may be eligible for study after being on stable and appropriate anti-infective therapy.
  • 1.2.13 Chemotherapy for active cancer.
  • 1.2.14 Pregnancy or breastfeeding.
  • 1.2.15 Use of immunosuppressive or immunomodulating agents within 8 weeks prior to study enrollment. Note: patients receiving oral corticosteroids for management of asthma or contact hypersensitivity for less than or equal to 14 days in duration will be allowed to enroll as long as it has been greater than or equal to 30 days since oral corticosteroid administration.
  • 1.2.16 Known immediate hypersensitivity to yeast or any of the vaccine components.
  • 1.2.17 Use of investigational agents within 4 weeks prior to study enrollment.
  • 1.2.18 Active external genital warts requiring treatment or CIN2/3
  • 1.2.19 Any clinically significant diseases (other than HIV infection) or findings during study screening that, in the opinion of the Principal Investigator or Lead Associate Investigator may interfere with the study.
  • Cohort 3 Inclusion and Exclusion Eligibility Criteria:
  • INCLUSION CRITERIA:
  • 1.3.1 Age 12 to 26 years
  • 1.3.2 Females and males
  • 1.3.3 HIV-negative
  • 1.3.4 Patients greater than or equal to 18 years willing to provide informed consent or parent/guardian willing to provide informed consent for minor children less than 18 years of age.
  • 1.3.5 Informed assent for patients 12-17 years of age (Optional at the discretion of the Principal Investigator and Parent/Guardian based on maturity level of minor)
  • 1.3.6 Willing to use acceptable forms of contraception, if applicable, or abstinence to prevent pregnancy.
  • EXCLUSION CRITERIA:
  • 1.3.7 Any of the following hematologic abnormalities:
  • Hemoglobin less than 10.0 g/dL
  • Neutrophil count less than 1500/mm(3)
  • Platelet count less than 75,000/mm(3)
  • PT or PTT greater than or equal to 1.5 times ULN (with the exception of patients with known clotting disorders or known lupus anticoagulant).
  • 1.3.8 Any of the following hepatic abnormalities
  • ALT/SGPT and/or AST/SGOT greater than 2.5 times ULN
  • Total Bilirubin greater than 1.5 times ULN unless attributable to protease inhibitor therapy.
  • 1.3.9 Positive tests (antibody and/or antigen) for HIV, hepatitis B and hepatitis C viruses, unless the result is consistent with prior vaccination or prior infection with full recovery.
  • 1.3.10 Acute infection requiring therapy at time of enrollment. Participants may be eligible for study after being on stable and appropriate anti-infective therapy.
  • 1.3.11 Chemotherapy for active cancer.
  • 1.3.12 Pregnancy or breastfeeding
  • 1.3.13 Use of immunosuppressive or immunomodulating agents within 8 weeks prior to study enrollment. Note: patients receiving oral corticosteroids for management of asthma or contact hypersensitivity for less than or equal to 14 days in duration will be allowed to enroll as long as it has been greater than or equal to 30 days since oral corticosteroid administration.
  • 1.3.14 Known immediate hypersensitivity to yeast or any of the vaccine components.
  • 1.3.15 Use of investigational agents within 4 weeks prior to study enrollment.
  • 1.3.16 Active external genital warts requiring treatment or carcinoma in-situ 2/3 (CIN2/3)
  • 1.3.17 Any clinically significant diseases or findings during study screening that, in the opinion of the Principal Investigator or Lead Associate Investigator may interfere with the study.

Exclusion

    Key Trial Info

    Start Date :

    June 29 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 4 2013

    Estimated Enrollment :

    26 Patients enrolled

    Trial Details

    Trial ID

    NCT00798265

    Start Date

    June 29 2009

    End Date

    February 4 2013

    Last Update

    November 20 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892